Free Trial

Natera (NTRA) Stock Forecast & Price Target

$101.15
-9.22 (-8.35%)
(As of 07/18/2024 ET)

Natera - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 16 Wall Street analysts who have issued ratings for Natera in the last 12 months, the stock has a consensus rating of "Buy." Out of the 16 analysts, 16 have given a buy rating for NTRA.

Consensus Price Target

$101.19
0.04% Upside
High Forecast$142.00
Average Forecast$101.19
Low Forecast$68.00

According to the 16 analysts' twelve-month price targets for Natera, the average price target is $101.19. The highest price target for NTRA is $142.00, while the lowest price target for NTRA is $68.00. The average price target represents a forecasted upside of 0.04% from the current price of $101.15.

TypeCurrent Forecast
7/20/23 to 7/19/24
1 Month Ago
6/20/23 to 6/19/24
3 Months Ago
4/21/23 to 4/20/24
1 Year Ago
7/20/22 to 7/20/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
16 Buy rating(s)
14 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$101.19$101.19$86.40$73.78
Forecasted Upside0.04% Upside24.67% Upside26.67% Upside46.48% Upside
Get Natera Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.

NTRA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NTRA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Natera Stock vs. The Competition

TypeNateraMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside0.04% Upside1,353.99% Upside9.11% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/3/2024Jefferies Financial Group
2 of 5 stars
 Initiated CoverageBuy$142.00+33.30%
5/14/2024Piper Sandler
2 of 5 stars
 Boost TargetOverweight ➝ Overweight$110.00 ➝ $120.00+16.13%
5/13/2024BTIG Research
2 of 5 stars
 Boost TargetBuy ➝ Buy$100.00 ➝ $125.00+21.11%
5/10/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$100.00 ➝ $130.00+23.66%
5/10/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$123.00 ➝ $137.00+30.23%
5/10/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$99.00 ➝ $117.00+22.45%
4/15/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$90.00 ➝ $100.00+7.93%
4/8/2024Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$117.00+21.23%
4/5/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$120.00+29.93%
2/20/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeStrong-Buy ➝ Outperform$68.00 ➝ $85.00+21.41%
1/30/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$78.00+17.49%
12/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$70.00+16.51%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$70.00+19.62%
11/10/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$70.00 ➝ $68.00+45.49%
11/9/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$76.00 ➝ $70.00+54.12%
8/4/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$70.00+37.34%
8/5/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$80.00 ➝ $100.00+94.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:47 AM ET.

NTRA Forecast - Frequently Asked Questions

What is Natera's forecast for 2024?

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Natera is $101.19, with a high forecast of $142.00 and a low forecast of $68.00.

Should I buy or sell Natera stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NTRA shares.

Does Natera's stock price have much upside?

According to analysts, Natera's stock has a predicted upside of 24.67% based on their 12-month stock forecasts.

What analysts cover Natera?

Natera has been rated by research analysts at BTIG Research, Canaccord Genuity Group, Jefferies Financial Group, Piper Sandler, Robert W. Baird, and TD Cowen in the past 90 days.

Do Wall Street analysts like Natera more than its competitors?

Analysts like Natera more than other "medical" companies. The consensus rating for Natera is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NTRA compares to other companies.


This page (NASDAQ:NTRA) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners